At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 107 enrolled
Drug / intervention
25 mg PF-05231023 +4 moredrug
Likely dose
25 mg PF-05231023from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Placebo-controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Iv Doses Of Pf-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin
In Brief
A Phase 1 clinical trial evaluating Placebo, 25 mg PF-05231023, and 3 other interventions for Diabetes Melliuts, Type 2. Completed, enrolled 107 participants across 17 sites.
Detailed Summary
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Melliuts, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartOct 2012
Primary CompletionAug 2013
Study CompletionSep 2013
TodayJul 2026
First PostedAug 27, 2012
Enrollment StartOct 1, 2012
Primary CompletionAug 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.8 years ago
Interventions
Placeboother
0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
25 mg PF-05231023drug
25 mg IV once a week for 4 weeks
50 mg PF-05231023drug
50 mg IV once a week for 4 weeks
100 mg PF-05231023drug
100 mg IV once a week for 4 weeks
150 mg PF-05231023drug
150 mg IV once a week for 4 weeks